Consistent with the NIH policy, NOT-OD-10-039, which was published in the NIH Guide to Grants and Contracts on January 8, 2010 and which requires a reduction to previously established commitments, NCI will issue non-competing awards to RPG mechanisms as follows:
For modular grants, the non-competing award will not be cut and will be based on the commitment of record for FY 2010; For categorical (non-modular) non-competing grants, the 3% cost of living adjustment (COLA) which is part of the commitment of record will be reduced to 2% and future year commitments will be reduced accordingly. Categorical non-competing grants which have not received a COLA, will not be cut.
This policy does not apply to projects supported by the Recovery Act or SBIR/STTRs – no cuts will be applied to those grants. Non-competing awards previously issued in FY 2010 at reduced levels will be revised to restore funds consistent with this final policy level.
The average cost of competing grants in FY2010 may increase 2 percent over the FY2009 competing average cost. This increase is consistent with the FY 2010 appropriation.
NCI will give funding priority to new and early stage investigators in its continued effort to support this population of investigator
Effective with the September 2009 National Cancer Advisory Board (NCAB) round (the first funding cycle of FY 2010) and for all three review rounds:
- Traditional R01s Type-1 and Type-2 R01 applications through the 15th percentile will be paid. Non-percentiled R01s will be paid on a case by case basis.
- New Exploratory Development (Type 1) R21 through the 15th percentile will be paid.
- New Small grants (Type 1) R03s through an impact score (formerly called priority score) of 30 will be paid.
- New AREA (Type 1) R15s through an impact score of 29 will be paid
- Program Project (P01) Applications (new and competing continuations)
P01s will continue to be paid on a case by case basis. P01 applicants will be notified of their potential for funding by the NCI program staff.
For the first funding cycles of FY 2010 (the first and second review rounds of the fiscal year), the pay line for large percentiled R01 applications is the 15.0 percentile. The payline for the third review round has not been established.
NCI has a strong commitment to new investigators. Applicants eligible for consideration as new R01 investigators under the FY 2010 appropriation will be paid using an extended payline of the 20.0 percentile. The current definition of new R01 investigators can be found in the Office of Extramural Research, NIH Web site at: http://grants1.nih.gov/grants/glossary.htm#N4.
NCI will give added consideration to investigators who are at the early stage of their research careers. The definition of Early Stage Investigators can be found at: http://grants.nih.gov/grants/glossary.htm#E.
NCI is committed to the review of applications submitted in response to RFAs previously announced and solicited for competition in FY 2010. As always, success rates for RFAs will depend on the amount of funds available, the number of applications submitted, programmatic priority and the scientific merit of the applications received. Please consult the Program Director listed on your summary statement if you have questions.
Amended applications submitted for the February/March, 2010 receipt dates (September 2010 NCAB), will be considered for funding under FY 2011 budget plans, which are not yet determined and may be different from these FY 2010 announced levels. FY 2011 begins on October 1, 2010.
During FY 2010, competing renewals (type-2s) will be funded at an average 3 percent increase over the current level and the new grants (type-1s) will be funded on average at a 17% reduction from the Initial Review Group recommended level. These levels of funding were in effect under the continuing resolution (CR). Thus, no restoration of competing awards made under the CR will be needed.